 Connection
David Fox to Multiple Sclerosis
This is a "connection" page, showing publications David Fox has written about Multiple Sclerosis.
|
|
| |
Connection Strength |
|
 |
|
 |
| |
0.500 |
|
|
|
-
Cooney LA, Lim N, Harris KM, Smilek DE, Bathala P, Stengelin M, Sigal G, Wohlstadter JN, Cencioni MT, Fernández Velasco JI, Mao-Draayer Y, Fox DA, Griffith LM, Nash R, Villar LM, Muraro PA. Autologous Hematopoietic Transplantation Reduces Brain Inflammatory and Axoglial Damage Biomarkers in Multiple Sclerosis. Neurol Neuroimmunol Neuroinflamm. 2026 Nov; 13(6):e200653.
Score: 0.164
-
Gurrea-Rubio M, Wang Q, Mills EA, Wu Q, Pitt D, Tsou PS, Fox DA, Mao-Draayer Y. Siponimod Attenuates Neuronal Cell Death Triggered by Neuroinflammation via NF?B and Mitochondrial Pathways. Int J Mol Sci. 2024 Feb 20; 25(5).
Score: 0.137
-
Ali A, Dwyer D, Wu Q, Wang Q, Dowling CA, Fox DA, Khanna D, Poland GA, Mao-Draayer Y. Characterization of humoral response to COVID mRNA vaccines in multiple sclerosis patients on disease modifying therapies. Vaccine. 2021 10 01; 39(41):6111-6116.
Score: 0.115
-
Li Y, Singer NG, Whitbred J, Bowen MA, Fox DA, Lin F. CD6 as a potential target for treating multiple sclerosis. Proc Natl Acad Sci U S A. 2017 03 07; 114(10):2687-2692.
Score: 0.084
|
Connection Strength
The connection strength for concepts is the sum of the scores for each matching publication.
Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
|